These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 25742515)

  • 1. Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
    Bellanger M; Demeneix B; Grandjean P; Zoeller RT; Trasande L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1256-66. PubMed ID: 25742515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union.
    Trasande L; Zoeller RT; Hass U; Kortenkamp A; Grandjean P; Myers JP; DiGangi J; Bellanger M; Hauser R; Legler J; Skakkebaek NE; Heindel JJ
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1245-55. PubMed ID: 25742516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male reproductive disorders, diseases, and costs of exposure to endocrine-disrupting chemicals in the European Union.
    Hauser R; Skakkebaek NE; Hass U; Toppari J; Juul A; Andersson AM; Kortenkamp A; Heindel JJ; Trasande L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1267-77. PubMed ID: 25742517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obesity, diabetes, and associated costs of exposure to endocrine-disrupting chemicals in the European Union.
    Legler J; Fletcher T; Govarts E; Porta M; Blumberg B; Heindel JJ; Trasande L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1278-88. PubMed ID: 25742518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Female Reproductive Disorders, Diseases, and Costs of Exposure to Endocrine Disrupting Chemicals in the European Union.
    Hunt PA; Sathyanarayana S; Fowler PA; Trasande L
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1562-70. PubMed ID: 27003299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis.
    Attina TM; Hauser R; Sathyanarayana S; Hunt PA; Bourguignon JP; Myers JP; DiGangi J; Zoeller RT; Trasande L
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):996-1003. PubMed ID: 27765541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Burden of disease and costs of exposure to endocrine disrupting chemicals in the European Union: an updated analysis.
    Trasande L; Zoeller RT; Hass U; Kortenkamp A; Grandjean P; Myers JP; DiGangi J; Hunt PM; Rudel R; Sathyanarayana S; Bellanger M; Hauser R; Legler J; Skakkebaek NE; Heindel JJ
    Andrology; 2016 Jul; 4(4):565-72. PubMed ID: 27003928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter to the Editor: Re: Neurobehavioral Deficits, Diseases, and Associated Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union.
    Middelbeek RJ; Veuger SA
    J Clin Endocrinol Metab; 2015 Jun; 100(6):L52-3. PubMed ID: 26047084
    [No Abstract]   [Full Text] [Related]  

  • 9. Human cost burden of exposure to endocrine disrupting chemicals. A critical review.
    Bond GG; Dietrich DR
    Arch Toxicol; 2017 Aug; 91(8):2745-2762. PubMed ID: 28528477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to the Letter by Middlebeek and Veuger.
    Bellanger M; Demeneix B; Grandjean P; Zoeller RT; Trasande L
    J Clin Endocrinol Metab; 2015 Jun; 100(6):L54-5. PubMed ID: 26047085
    [No Abstract]   [Full Text] [Related]  

  • 11. Exposure to Endocrine Disrupting Chemicals in Canada: Population-Based Estimates of Disease Burden and Economic Costs.
    Malits J; Naidu M; Trasande L
    Toxics; 2022 Mar; 10(3):. PubMed ID: 35324771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in neurodevelopmental disability burden due to early life chemical exposure in the USA from 2001 to 2016: A population-based disease burden and cost analysis.
    Gaylord A; Osborne G; Ghassabian A; Malits J; Attina T; Trasande L
    Mol Cell Endocrinol; 2020 Feb; 502():110666. PubMed ID: 31952890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost of disorders of the brain in Europe 2010.
    Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jönsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen HC; Stovner LJ; Vallat JM; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen HU; Jönsson B; Olesen J;
    Eur Neuropsychopharmacol; 2011 Oct; 21(10):718-79. PubMed ID: 21924589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impacts of environmentally attributable childhood health outcomes in the European Union.
    Bartlett ES; Trasande L
    Eur J Public Health; 2014 Feb; 24(1):21-6. PubMed ID: 23748596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease burden attributable to endocrine-disrupting chemicals exposure in China: A case study of phthalates.
    Cao Y; Li L; Shen K; Liu J
    Sci Total Environ; 2019 Apr; 662():615-621. PubMed ID: 30699382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic cost of autism in the UK.
    Knapp M; Romeo R; Beecham J
    Autism; 2009 May; 13(3):317-36. PubMed ID: 19369391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic burden of cancer across the European Union: a population-based cost analysis.
    Luengo-Fernandez R; Leal J; Gray A; Sullivan R
    Lancet Oncol; 2013 Nov; 14(12):1165-74. PubMed ID: 24131614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic Burden of Bladder Cancer Across the European Union.
    Leal J; Luengo-Fernandez R; Sullivan R; Witjes JA
    Eur Urol; 2016 Mar; 69(3):438-47. PubMed ID: 26508308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European Union-28: An annualised cost-of-illness model for venous thromboembolism.
    Barco S; Woersching AL; Spyropoulos AC; Piovella F; Mahan CE
    Thromb Haemost; 2016 Apr; 115(4):800-8. PubMed ID: 26607486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of methods for calculating the health costs of endocrine disrupters: a case study on triclosan.
    Prichystalova R; Fini JB; Trasande L; Bellanger M; Demeneix B; Maxim L
    Environ Health; 2017 Jun; 16(1):55. PubMed ID: 28599657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.